ClinicalTrials.gg
RecruitingNCT06258642Updated Aug 20, 2025

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

An interventional study of Irinotecan Liposome and Anlotinib in Small Cell Lung Cancer Recurrent, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Fudan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies testing anlotinib in Small Cell Lung Carcinoma — 15 open to participants now, 16 under way, 2 of them phase 3. anlotinib · Small Cell Lung Carcinoma.

Planned enrollment
19th of 35
39 · median 40
Started
2024
with 1 other
No phase
2 of 35
1 open now
Primary completion
2026-04
later than 3 of 15 live
Registered
22nd of 35
by date
Lead sponsor
2 of 35
Fudan University

Among the 35 studies testing anlotinib in Small Cell Lung Carcinoma, this one is the 19th largest by planned enrollment, is one of 2 that started in 2024, is one of 2 with no phase, reaches primary completion later than 3 of the 15 other live ones, and was the 22nd registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

15 of the 35 studies testing anlotinib in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About anlotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing anlotinib in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This study is a single arm, multi-center, prospective clinical trial. The purpose of this study is to evaluate the efficacy and safety of liposomal irinotecan combined with anlotinib hydrochloride for relapsed small-cell lung cancer, who have progressed on or less than 6 month after platinum-based first-line therapy.

Read the detailed description

Patients will receive irinotecan liposome injection at 70 mg/m\^2 intravenously, on Days 1 of every 14-day cycle and anlotinib (12 mg/day) for 2 consecutive weeks and then discontinued for 1 week. The treatment is continued until disease progression or intolerable toxicity.

03

Conditions studied

  • Small Cell Lung Cancer Recurrent

Keywords

  • Small Cell Lung Cancer
  • liposomal irinotecan
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Aged ≥18 and ≤75 years old;
  • 2) or cytologically confirmed small cell lung cancer;
  • 3) At least one according to the (RECIST) 1.1;
  • 4) Radiologically confirmed recurrence or progression within 6months after platinum-based, chemotherapy or chemoradiation therapy;
  • 5) (ECOG) performance status score of 0-2;
  • 6) Expected survival of more than 3 months;
  • 7) Recovered from the effects of any prior chemotherapy, surgery, radiotherapy or other anti-neoplastic therapy (recovered to no more than Grade 1 of 5.0 criteria or baseline, with the exception of alopecia or other toxicity without safety concerns by the investigators' judgment);
  • 8) Adequate major organ function, patients should meet the following criteria:

    ① Bone marrow function: absolute neutrophile count (ANC)≥1.5×109/L, (PLT)≥100×109/L, (Hb)≥90g/L, white blood cell (WBC)≥3.0×109/L;

    ② Hepatic function: total ≤1.5× value(ULN); and AST≤2.5×ULN,liver :≤5×ULN;

    ③ Renal function: serum creatinine ≤1.5×ULN and rate ≥60 mL/min;

    ④ Coagulation function:(APTT)、International normalized ratio(INR)、prothrombin time (PT)≤1.5×ULN;

    ⑤ urine routines show urine protein \< 2+(when urine protein >2+, urine protein quantity\< 1.0 g during 24 hours before 7 days);

  • 9) Patients fully understood and volunteered to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • 1) Patients with large cell neuroendocrine lung carcinoma or combined small cell lung carcinoma;
  • 2) Patients with asymptomatic central nervous system (CNS) prior to enrollment or those who have CNS disease requiring increase in the dose of . (Patients with controlled can participate in the trial);
  • 3) Patients with uncontrolled pleural effusion, abdominal effusion and pericardial effusion after repeated drainage or other treatment within 2 weeks prior to the first dose of this study, and those judged by the clinicians to be unsuitable for the study;
  • 4) Diagnosed with any other cancer within the past 5 years (except for cured basal cell carcinoma and in situ cancer);
  • 5) Patients who have received prior irinotecan/ liposomal irinotecan and anti-angiogenic drugs such as anlotinib and bevacizumab , etc.
  • 6) Concomitant use of strong inducers within 2 weeks or strong CYP3A4 inhibitors or strong UGT1A1 inhibitors within 1 week of the first dose of the study drug;
  • 7) Patients who have received other anti-tumor treatments(including radiotherapy, chemotherapy, immunotherapy, etc.) within 4 weeks before the first dose;
  • 8) Combined with uncontrolled systemic diseases, including unstable angina, myocardial infarction, congestive heart failure, severe ventricular arrhythmia , etc.
  • 9) Severe pulmonary disease within 6 months prior to enrolment, such as interstitial pneumonia, pulmonary fibrosis, radiation induced pneumonitis requiring steroid therapy, and other moderate and severe lung diseases which affect lung function;
  • 10) Arterial/venous thrombosis within 6 months prior to enrollment, e.g. cerebrovascular accident (include temporary ischemic attack), deep venous thrombosis, pulmonary embolism.
  • 11) Symptoms or propensity to bleed within 3 months prior to screening (include gastrointestinal hemorrhage, ulcerative gastric bleeding, fecal occult blood 2+ or above, vasculitis);
  • 12) Patients had undergone major surgical procedure(except for diagnostic surgery) within 4 weeks before dosing or was scheduled to receive major procedure during the study;
  • 13) unhealed wounds, ulcers or fractures;
  • 14) Imaging showed tumors have involved important blood vessels or by investigators determine likely during the follow-up study and cause fatal hemorrhage;
  • 15) Active and uncontrolled bacterial, viral, fungal infection requiring systemic treatment;
  • 16) Active /C, or infection;
  • 17) Known intolerance or allergy to therapeutic drugs and their ;
  • 18) gastrointestinal disorder, including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 1;
  • 19) Pregnant or breast feeding;
  • 20) Patient is not suitable for the study in the investigator's opinion.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Irinotecan Liposome and anlotinib

    The treatment is continued until disease progression or intolerable toxicity

    Drug: Irinotecan Liposome · Drug: Anlotinib

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate(ORR)

    To evaluate anti-tumor efficacy

    Time frame: From date of first dose until the date of first documented progression, assessed up to 24 months

Secondary outcomes

  1. Disease control rate (DCR)

    To evaluate anti-tumor efficacy

    Time frame: From date of first dose until the date of first documented progression, assessed up to 24 months

  2. Duration of Response(DoR)

    To evaluate anti-tumor efficacy

    Time frame: From date of first dose until the date of first documented progression, assessed up to 24 months

  3. Progression-Free Survival (PFS)

    To evaluate anti-tumor efficacy

    Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  4. Overall Survival (OS)

    To evaluate anti-tumor efficacy

    Time frame: From date of first dose until the date of death from any cause , assessed up to 24 months

  5. Incidence and severity of adverse events

    To evaluate the safety

    Time frame: date of the first dose to 28 days after permanent treatment termination

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2026, 24 months after the start.

Of 45 non-industry interventional studies with no phase under Small Cell Lung Carcinoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 73. This study's planned 24 months is below that.

Counting every sponsor, half of 47 studies reached it within 52 months; a quarter within 25 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 14, 2024
StartActual
Apr 17, 2024
Primary completionEst.
Apr 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06258642
Lead sponsor
Fudan University
Responsible party
Jialei Wang (Doctor, Fudan University) — Principal investigator
First posted
Feb 14, 2024
Start date
Apr 17, 2024
Primary completion
Apr 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 20, 2025

Study contacts

Jialei Wang, Doctor
Contact
luwangjialei@hotmail.com
021-64175590 ext. 88900
Jialei Wang, Doctor
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan sucrosofate · Anlotinib

Start the discussion